☰

Susan Zolla-Pazner - Publications

Affiliations: 
New York University, New York, NY, United States 
Area:
Microbiology Biology, Virology Biology, Public Health
Tree Info Similar researchers PubMed Report error

287 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Hioe CE, Liu X, Banin AN, Heindel DW, Klingler JR, Rao PG, Luo CC, Jiang X, Pandey S, Ordonez T, Barnette P, Totrov M, Zhu J, Na das A, Zolla-Pazner S, et al. Corrigendum: Vaccination with immune complexes modulates the elicitation of functional antibodies against HIV-1. Frontiers in Immunology. 14: 1329069. PMID 38022586 DOI: 10.3389/fimmu.2023.1329069  0.409
2023 Schommers P, Kim DS, Schlotz M, Kreer C, Eggeling R, Hake A, Stecher M, Park J, Radford CE, Dingens AS, Ercanoglu MS, Gruell H, Odidika S, Dahlhaus M, Gieselmann L, ... ... Zolla-Pazner S, et al. Dynamics and durability of HIV-1 neutralization are determined by viral replication. Nature Medicine. PMID 37957379 DOI: 10.1038/s41591-023-02582-3  0.509
2023 Hioe CE, Liu X, Banin AN, Heindel DW, Klingler J, Rao PG, Luo CC, Jiang X, Pandey S, Ordonez T, Barnette P, Totrov M, Zhu J, Nádas A, Zolla-Pazner S, et al. Vaccination with immune complexes modulates the elicitation of functional antibodies against HIV-1. Frontiers in Immunology. 14: 1271686. PMID 37854587 DOI: 10.3389/fimmu.2023.1271686  0.479
2022 Yang Z, Dam KA, Gershoni JM, Zolla-Pazner S, Bjorkman PJ. Antibody Recognition of CD4-Induced Open HIV-1 Env Trimers. Journal of Virology. e0108222. PMID 36448805 DOI: 10.1128/jvi.01082-22  0.508
2022 Prévost J, Anand SP, Rajashekar JK, Zhu L, Richard J, Goyette G, Medjahed H, Gendron-Lepage G, Chen HC, Chen Y, Horwitz JA, Grunst MW, Zolla-Pazner S, Haynes BF, Burton DR, et al. HIV-1 Vpu restricts Fc-mediated effector functions in vivo. Cell Reports. 41: 111624. PMID 36351384 DOI: 10.1016/j.celrep.2022.111624  0.473
2022 Fox A, Liu X, Zolla-Pazner S, Powell RL. Impact of IgG Isotype on the Induction of Antibody-Dependent Cellular Phagocytosis of HIV by Human Milk Leukocytes. Frontiers in Immunology. 13: 831767. PMID 35592337 DOI: 10.3389/fimmu.2022.831767  0.464
2022 Fox A, Marino J, Amanat F, Oguntuyo KY, Hahn-Holbrook J, Lee B, Zolla-Pazner S, Powell RL. The IgA in milk induced by SARS-CoV-2 infection is comprised of mainly secretory antibody that is neutralizing and highly durable over time. Plos One. 17: e0249723. PMID 35263323 DOI: 10.1371/journal.pone.0249723  0.314
2022 Weiss S, Itri V, Pan R, Jiang X, Luo CC, Morris L, Malherbe DC, Barnette P, Alexander J, Kong XP, Haigwood NL, Hessell AJ, Duerr R, Zolla-Pazner S. Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines. Nature Communications. 13: 903. PMID 35173151 DOI: 10.1038/s41467-022-28450-1  0.473
2022 Hioe CE, Li G, Liu X, Tsahouridis O, He X, Funaki M, Klingler J, Tang AF, Feyznezhad R, Heindel DW, Wang XH, Spencer DA, Hu G, Satija N, Prévost J, ... ... Zolla-Pazner S, et al. Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice. Plos Pathogens. 18: e1010183. PMID 34986207 DOI: 10.1371/journal.ppat.1010183  0.584
2021 Klingler J, Lambert GS, Itri V, Liu S, Bandres JC, Enyindah-Asonye G, Liu X, Simon V, Gleason CR, Kleiner G, Chiu HP, Hung CT, Kowdle S, Amanat F, Lee B, ... Zolla-Pazner S, et al. Detection of Antibody Responses Against SARS-CoV-2 in Plasma and Saliva From Vaccinated and Infected Individuals. Frontiers in Immunology. 12: 759688. PMID 34987505 DOI: 10.3389/fimmu.2021.759688  0.311
2021 Lee M, Changela A, Gorman J, Rawi R, Bylund T, Chao CW, Lin BC, Louder MK, Olia AS, Zhang B, Doria-Rose NA, Zolla-Pazner S, Shapiro L, Chuang GY, Kwong PD. Extended antibody-framework-to-antigen distance observed exclusively with broad HIV-1-neutralizing antibodies recognizing glycan-dense surfaces. Nature Communications. 12: 6470. PMID 34753907 DOI: 10.1038/s41467-021-26579-z  0.489
2021 Oguntuyo KY, Stevens CS, Hung CT, Ikegame S, Acklin JA, Kowdle SS, Carmichael JC, Chiu HP, Azarm KD, Haas GD, Amanat F, Klingler J, Baine I, Arinsburg S, Bandres JC, ... ... Zolla-Pazner S, et al. Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera. Mbio. 12. PMID 33593976 DOI: 10.1128/mBio.02492-20  0.338
2020 Upadhyay C, Feyznezhad R, Cao L, Chan KW, Liu K, Yang W, Zhang H, Yolitz J, Arthos J, Nadas A, Kong XP, Zolla-Pazner S, Hioe CE. Signal peptide of HIV-1 envelope modulates glycosylation impacting exposure of V1V2 and other epitopes. Plos Pathogens. 16: e1009185. PMID 33370382 DOI: 10.1371/journal.ppat.1009185  0.405
2020 Klingler J, Weiss S, Itri V, Liu X, Oguntuyo KY, Stevens C, Ikegame S, Hung CT, Enyindah-Asonye G, Amanat F, Baine I, Arinsburg S, Bandres JC, Kojic EM, Stoever J, ... ... Zolla-Pazner S, et al. Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2. The Journal of Infectious Diseases. PMID 33367897 DOI: 10.1093/infdis/jiaa784  0.338
2020 Klingler J, Weiss S, Itri V, Liu X, Oguntuyo KY, Stevens C, Ikegame S, Hung CT, Enyindah-Asonye G, Amanat F, Baine I, Arinsburg S, Bandres JC, Kojic EM, Stoever J, ... ... Zolla-Pazner S, et al. Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2. Medrxiv : the Preprint Server For Health Sciences. PMID 33173891 DOI: 10.1101/2020.08.18.20177303  0.338
2020 Devasundaram S, Rosati M, Valentin A, Weiss S, Itri V, Trinh HV, Bear J, Chowdhury B, LaBranche CC, Montefiori D, Ferrari G, Rao M, Kong XP, Zolla-Pazner S, Pavlakis GN, et al. Priming with DNA expressing trimeric HIV V1V2 alters the immune hierarchy favoring the development of V2-specific antibodies in rhesus macaques. Journal of Virology. PMID 33087466 DOI: 10.1128/JVI.01193-20  0.433
2020 Weiss S, Klingler J, Hioe C, Amanat F, Baine I, Arinsburg S, Kojic EM, Stoever J, Liu STH, Jurczyszak D, Bermudez-Gonzalez M, Simon V, Krammer F, Zolla-Pazner S. A High Through-Put Assay For Circulating Antibodies Directed Against The S Protein Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2). The Journal of Infectious Diseases. PMID 32860510 DOI: 10.1093/Infdis/Jiaa531  0.441
2020 Oguntuyo KY, Stevens CS, Hung CT, Ikegame S, Acklin JA, Kowdle SS, Carmichael JC, Chiu HP, Azarm KD, Haas GD, Amanat F, Klingler J, Baine I, Arinsburg S, Bandres JC, ... ... Zolla-Pazner S, et al. Quantifying absolute neutralization titers against SARS-CoV-2 by a standardized virus neutralization assay allows for cross-cohort comparisons of COVID-19 sera. Medrxiv : the Preprint Server For Health Sciences. PMID 32817961 DOI: 10.1101/2020.08.13.20157222  0.317
2020 Powell RL, Weiss S, Fox A, Liu X, Itri V, Jiang X, Luo CC, Spencer DA, Pandey S, Cheever T, Fuller DH, Totrov M, Hessell AJ, Haigwood NL, Kong XP, ... Zolla-Pazner S, et al. An HIV vaccine targeting the V2 region of Envelope induces a highly durable polyfunctional Fc-mediated antibody response in rhesus macaques. Journal of Virology. PMID 32554699 DOI: 10.1128/Jvi.01175-20  0.521
2020 Lai JI, Eszterhas SK, Brooks SA, Guo C, Zolla-Pazner S, Seaman MS, Bailey-Kellogg C, Griswold KE, Ackerman ME. Induction of cross-reactive HIV-1 specific antibody responses by engineered V1V2 immunogens with reduced conformational plasticity. Vaccine. PMID 32192810 DOI: 10.1016/J.Vaccine.2020.03.010  0.546
2019 Hessell AJ, Powell R, Jiang X, Luo C, Weiss S, Dussupt V, Itri V, Fox A, Shapiro MB, Pandey S, Cheever T, Fuller DH, Park B, Krebs SJ, Totrov M, ... ... Zolla-Pazner S, et al. Multimeric Epitope-Scaffold HIV Vaccines Target V1V2 and Differentially Tune Polyfunctional Antibody Responses. Cell Reports. 28: 877-895.e6. PMID 31340151 DOI: 10.1016/J.Celrep.2019.06.074  0.589
2019 Zolla-Pazner S, Gilbert PB. REVISITING THE CORRELATE OF REDUCED HIV INFECTION RISK IN THE RV144 VACCINE TRIAL. Journal of Virology. PMID 31189712 DOI: 10.1128/Jvi.00629-19  0.478
2019 Tuen M, Bimela JS, Banin AN, Ding S, Harkins GW, Weiss S, Itri V, Durham AR, Porcella SF, Soni S, Mayr L, Meli J, Torimiro JN, Tongo M, Wang X, ... ... Zolla-Pazner S, et al. Immune Correlates of Disease Progression in Linked HIV-1 Infection. Frontiers in Immunology. 10: 1062. PMID 31139189 DOI: 10.3389/Fimmu.2019.01062  0.547
2019 Zolla-Pazner S, Alvarez R, Kong XP, Weiss S. Vaccine-induced V1V2-specific antibodies control and or protect against infection with HIV, SIV and SHIV. Current Opinion in Hiv and Aids. PMID 30994501 DOI: 10.1097/Coh.0000000000000551  0.578
2019 Liu L, Li L, Nanfack A, Mayr LM, Soni S, Kohutnicki A, Agyingi L, Wang XH, Tuen M, Shao Y, Totrov M, Zolla-Pazner S, Kong XP, Duerr R, Gorny MK. Anti-V2 antibody deficiency in individuals infected with HIV-1 in Cameroon. Virology. 529: 57-64. PMID 30665098 DOI: 10.1016/J.Virol.2019.01.011  0.574
2018 Powell RLR, Fox A, Itri V, Zolla-Pazner S. Primary Human Neutrophils Exhibit a Unique HIV-Directed Antibody-Dependent Phagocytosis Profile. Journal of Innate Immunity. 1-10. PMID 30557875 DOI: 10.1159/000494371  0.584
2018 Hioe CE, Kumar R, Upadhyay C, Jan M, Fox A, Itri V, Peachman KK, Rao M, Liu L, Lo NC, Tuen M, Jiang X, Kong XP, Zolla-Pazner S. Modulation of Antibody Responses to the V1V2 and V3 Regions of HIV-1 Envelope by Immune Complex Vaccines. Frontiers in Immunology. 9: 2441. PMID 30416503 DOI: 10.3389/Fimmu.2018.02441  0.537
2018 Wen Y, Trinh HV, Linton CE, Tani C, Norais N, Martinez-Guzman D, Ramesh P, Sun Y, Situ F, Karaca-Griffin S, Hamlin C, Onkar S, Tian S, Hilt S, Malyala P, ... ... Zolla-Pazner S, et al. Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant. Plos One. 13: e0194266. PMID 29698406 DOI: 10.1371/Journal.Pone.0194266  0.566
2018 Cheng HD, Grimm SK, Gilman MS, Gwom LC, Sok D, Sundling C, Donofrio G, Hedestam GBK, Bonsignori M, Haynes BF, Lahey TP, Maro I, von Reyn CF, Gorny MK, Zolla-Pazner S, et al. Fine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site. Jci Insight. 3. PMID 29515029 DOI: 10.1172/Jci.Insight.97018  0.564
2018 Hessell AJ, Shapiro MB, Powell R, Malherbe DC, McBurney SP, Pandey S, Cheever T, Sutton WF, Kahl C, Park B, Zolla-Pazner S, Haigwood NL. Reduced cell-associated DNA and improved viral control in macaques following passive transfer of a single anti-V2 monoclonal antibody and repeated SHIV challenges. Journal of Virology. PMID 29514914 DOI: 10.1128/Jvi.02198-17  0.597
2018 Yates NL, deCamp AC, Korber BT, Liao HX, Irene C, Pinter A, Peacock J, Harris LJ, Sawant S, Hraber P, Shen X, Rerks-Ngarm S, Pitisuttithum P, Nitayapan S, Berman PW, ... ... Zolla-Pazner S, et al. HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees. Journal of Virology. PMID 29386288 DOI: 10.1128/Jvi.01843-17  0.574
2018 Upadhyay C, Feyznezhad R, Yang W, Zhang H, Zolla-Pazner S, Hioe CE. Alterations of HIV-1 envelope phenotype and antibody-mediated neutralization by signal peptide mutations. Plos Pathogens. 14: e1006812. PMID 29370305 DOI: 10.1371/Journal.Ppat.1006812  0.558
2018 Balasubramanian P, Williams C, Shapiro MB, Sinangil F, Higgins K, Nádas A, Totrov M, Kong XP, Fiore-Gartland AJ, Haigwood NL, Zolla-Pazner S, Hioe CE. Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials. Scientific Reports. 8: 542. PMID 29323175 DOI: 10.1038/S41598-017-18863-0  0.513
2017 Mayr LM, Decoville T, Schmidt S, Laumond G, Klingler J, Ducloy C, Bahram S, Zolla-Pazner S, Moog C. Non-neutralizing Antibodies Targeting the V1V2 Domain of HIV Exhibit Strong Antibody-Dependent Cell-mediated Cytotoxic Activity. Scientific Reports. 7: 12655. PMID 28978939 DOI: 10.1038/S41598-017-12883-6  0.62
2017 Horwitz JA, Bar-On Y, Lu CL, Fera D, Lockhart AAK, Lorenzi JCC, Nogueira L, Golijanin J, Scheid JF, Seaman MS, Gazumyan A, Zolla-Pazner S, Nussenzweig MC. Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo. Cell. PMID 28757252 DOI: 10.1016/J.Cell.2017.06.048  0.624
2017 Powell RLR, Totrov M, Itri V, Liu X, Fox A, Zolla-Pazner S. Plasticity and Epitope Exposure of the HIV-1 Envelope Trimer. Journal of Virology. PMID 28615206 DOI: 10.1128/Jvi.00410-17  0.495
2017 Balasubramanian P, Kumar R, Williams C, Itri V, Wang S, Lu S, Hessell AJ, Haigwood NL, Sinangil F, Higgins KW, Liu L, Li L, Nyambi P, Gorny MK, Totrov M, ... ... Zolla-Pazner S, et al. Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination. Vaccine. PMID 28185743 DOI: 10.1016/J.Vaccine.2016.11.107  0.598
2017 Musich T, Li L, Liu L, Zolla-Pazner S, Robert-Guroff M, Gorny MK. Monoclonal Antibodies to V2, V3, the CD4-binding site and gp41 HIV-1 Mediate Phagocytosis in a Dose-dependent Manner. Journal of Virology. PMID 28122974 DOI: 10.1128/Jvi.02325-16  0.572
2016 Zolla-Pazner S. Non-neutralizing antibody functions for protection and control HIV in humans and SIV and SHIV in non-human primates. Aids (London, England). 30: 2551-2553. PMID 27753680 DOI: 10.1097/Qad.0000000000001200  0.528
2016 Tsukrov D, McFarren A, Morgenstern A, Bruchertseifer F, Dolce E, Gorny MK, Zolla-Pazner S, Berman JW, Schoenbaum E, Zingman BS, Casadevall A, Dadachova E. Combination of Antiretroviral Drugs and Radioimmunotherapy Specifically Kills Infected Cells from HIV-Infected Individuals. Frontiers in Medicine. 3: 41. PMID 27725930 DOI: 10.3389/Fmed.2016.00041  0.535
2016 Jiang X, Totrov M, Li W, Sampson JM, Williams C, Lu H, Wu X, Lu S, Wang S, Zolla-Pazner S, Kong XP. Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits. Journal of Virology. PMID 27707920 DOI: 10.1128/Jvi.01409-16  0.473
2016 Zolla-Pazner S, Powell R, Yahyaei S, Williams C, Jiang X, Li W, Lu S, Wang S, Upadhyay C, Hioe CE, Totrov M, Kong X. RATIONALLY-DESIGNED VACCINES TARGETING THE V2 REGION OF HIV-1 gp120 INDUCE A FOCUSED, CROSS CLADE-REACTIVE, BIOLOGICALLY FUNCTIONAL ANTIBODY RESPONSE. Journal of Virology. PMID 27630234 DOI: 10.1128/Jvi.01403-16  0.62
2016 von Bredow B, Arias JF, Heyer LN, Moldt B, Le K, Robinson JE, Zolla-Pazner S, Burton DR, Evans DT. Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-specific Monoclonal Antibodies. Journal of Virology. PMID 27122574 DOI: 10.1128/Jvi.00347-16  0.636
2016 Hessell AJ, McBurney S, Pandey S, Sutton W, Liu L, Li L, Totrov M, Zolla-Pazner S, Haigwood NL, Gorny MK. Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides. Vaccine. PMID 27102818 DOI: 10.1016/J.Vaccine.2016.04.027  0.546
2016 Kumar R, Williams C, Itri V, Wang S, Lu S, Hessell A, Higgins K, Liu L, Haigwood N, Sinangil F, Gorny M, Totrov M, Kong X, Nadas A, Zolla-Pazner S, et al. P-C16 Differential Induction of Anti-V3 Crown Antibodies with Cradle and Ladle-Binding Modes in Response to HIV-1 Envelope Vaccination Journal of Acquired Immune Deficiency Syndromes. 71: 84. DOI: 10.1097/01.Qai.0000479635.49430.16  0.54
2016 Pan R, Jia M, Li L, Robinson J, Zolla-Pazner S, Gorny M, Wu X, Kong X. P-D7 Structural mimicry of the antigen binding modes of rhesus macaque and human anti-gp120 V3 antibodies Journal of Acquired Immune Deficiency Syndromes. 71: 94. DOI: 10.1097/01.Qai.0000479632.57053.Bf  0.454
2015 Peachman KK, Karasavvas N, Chenine AL, McLinden R, Rerks-Ngarm S, Jaranit K, Nitayaphan S, Pitisuttithum P, Tovanabutra S, Zolla-Pazner S, Michael NL, Kim JH, Alving CR, Rao M. Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor. Plos One. 10: e0143895. PMID 26625359 DOI: 10.1371/Journal.Pone.0143895  0.565
2015 McFarren A, Lopez L, Williams DW, Veenstra M, Bryan RA, Goldsmith A, Morgenstern A, Bruchertseifer F, Zolla-Pazner S, Gorny MK, Eugenin EA, Berman JW, Dadachova E. A fully human antibody to gp41 selectively eliminates HIV-infected cells that transmigrated across a model human blood brain barrier. Aids (London, England). PMID 26595540 DOI: 10.1097/Qad.0000000000000968  0.544
2015 Shen G, Upadhyay C, Zhang J, Pan R, Zolla-Pazner S, Kong XP, Hioe CE. Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies. Plos One. 10: e0141233. PMID 26491873 DOI: 10.1371/Journal.Pone.0141233  0.607
2015 Zolla-Pazner S, Cohen SS, Boyd D, Kong XP, Seaman M, Nussenzweig M, Klein F, Overbaugh J, Totrov M. Structure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors that Affect Neutralization Sensitivity. Journal of Virology. PMID 26491157 DOI: 10.1128/Jvi.01645-15  0.581
2015 Moody MA, Gao F, Gurley TC, Amos JD, Kumar A, Hora B, Marshall DJ, Whitesides JF, Xia SM, Parks R, Lloyd KE, Hwang KK, Lu X, Bonsignori M, Finzi A, ... ... Zolla-Pazner S, et al. Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. Cell Host & Microbe. 18: 354-62. PMID 26355218 DOI: 10.1016/J.Chom.2015.08.006  0.624
2015 Prentice HA, Tomaras GD, Geraghty DE, Apps R, Fong Y, Ehrenberg PK, Rolland M, Kijak GH, Krebs SJ, Nelson W, DeCamp A, Shen X, Yates NL, Zolla-Pazner S, Nitayaphan S, et al. HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition. Science Translational Medicine. 7: 296ra112. PMID 26180102 DOI: 10.1126/Scitranslmed.Aab4005  0.54
2015 Kumar R, Pan R, Upadhyay C, Mayr L, Cohen S, Wang XH, Balasubramanian P, Nádas A, Seaman MS, Zolla-Pazner S, Gorny MK, Kong XP, Hioe CE. Functional and structural characterization of human V3-specific monoclonal antibody 2424 with neutralizing activity against HIV-1 JRFL. Journal of Virology. PMID 26109728 DOI: 10.1128/Jvi.01280-15  0.632
2015 Mayr LM, Zolla-Pazner S. Antibodies Targeting the Envelope of HIV-1. Microbiology Spectrum. 3: AID-0025-2014. PMID 26104552 DOI: 10.1128/Microbiolspec.Aid-0025-2014  0.598
2015 Do Kwon Y, Pancera M, Acharya P, Georgiev IS, Crooks ET, Gorman J, Joyce MG, Guttman M, Ma X, Narpala S, Soto C, Terry DS, Yang Y, Zhou T, Ahlsen G, ... ... Zolla-Pazner S, et al. Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. Nature Structural & Molecular Biology. 22: 522-31. PMID 26098315 DOI: 10.1038/Nsmb.3051  0.541
2015 Wise MC, Hutnick NA, Pollara J, Myles DJ, Williams C, Yan J, LaBranche CC, Khan AS, Sardesai NY, Montefiori D, Barnett SW, Zolla-Pazner S, Ferrari G, Weiner DB. An enhanced synthetic multi-clade DNA prime induces improved cross-clade reactive functional antibodies when combined with an adjuvanted protein boost in non-human primates. Journal of Virology. PMID 26085155 DOI: 10.1128/Jvi.00652-15  0.531
2015 Pan R, Gorny MK, Zolla-Pazner S, Kong XP. The V1V2 Region of HIV-1 gp120 Forms a Five-Stranded Beta Barrel. Journal of Virology. 89: 8003-10. PMID 26018158 DOI: 10.1128/Jvi.00754-15  0.544
2015 Wieczorek L, Krebs SJ, Kalyanaraman V, Whitney S, Tovanabutra S, Moscoso CG, Sanders-Buell E, Williams C, Slike B, Molnar S, Dussupt V, Alam SM, Chenine AL, Tong T, Hill EL, ... ... Zolla-Pazner S, et al. Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research. Journal of Virology. 89: 7478-93. PMID 25972551 DOI: 10.1128/Jvi.00412-15  0.623
2015 Li L, Wang XH, Williams C, Volsky B, Steczko O, Seaman MS, Luthra K, Nyambi P, Nadas A, Giudicelli V, Lefranc MP, Zolla-Pazner S, Gorny MK. A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site. Molecular Immunology. 66: 364-74. PMID 25965315 DOI: 10.1016/J.Molimm.2015.04.011  0.594
2015 Moody MA, Gao F, Gurley TC, Amos JD, Kumar A, Hora B, Marshall DJ, Whitesides JF, Xia SM, Parks R, Lloyd KE, Hwang KK, Lu X, Bonsignori M, Finzi A, ... ... Zolla-Pazner S, et al. Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses Cell Host and Microbe. 18: 354-362. DOI: 10.1016/j.chom.2015.08.006  0.435
2014 Zolla-Pazner S, Edlefsen PT, Rolland M, Kong XP, deCamp A, Gottardo R, Williams C, Tovanabutra S, Sharpe-Cohen S, Mullins JI, deSouza MS, Karasavvas N, Nitayaphan S, Rerks-Ngarm S, Pitisuttihum P, et al. Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses. Ebiomedicine. 1: 37-45. PMID 25599085 DOI: 10.1016/J.Ebiom.2014.10.022  0.555
2014 Klein F, Nogueira L, Nishimura Y, Phad G, West AP, Halper-Stromberg A, Horwitz JA, Gazumyan A, Liu C, Eisenreich TR, Lehmann C, Fätkenheuer G, Williams C, Shingai M, Martin MA, ... ... Zolla-Pazner S, et al. Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants. The Journal of Experimental Medicine. 211: 2361-72. PMID 25385756 DOI: 10.1084/Jem.20141050  0.597
2014 Upadhyay C, Mayr LM, Zhang J, Kumar R, Gorny MK, Nádas A, Zolla-Pazner S, Hioe CE. Distinct mechanisms regulate exposure of neutralizing epitopes in the V2 and V3 loops of HIV-1 envelope. Journal of Virology. 88: 12853-65. PMID 25165106 DOI: 10.1128/Jvi.02125-14  0.613
2014 Chung AW, Crispin M, Pritchard L, Robinson H, Gorny MK, Yu X, Bailey-Kellogg C, Ackerman ME, Scanlan C, Zolla-Pazner S, Alter G. Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function. Aids (London, England). 28: 2523-30. PMID 25160934 DOI: 10.1097/Qad.0000000000000444  0.51
2014 Li SS, Gilbert PB, Tomaras GD, Kijak G, Ferrari G, Thomas R, Pyo CW, Zolla-Pazner S, Montefiori D, Liao HX, Nabel G, Pinter A, Evans DT, Gottardo R, Dai JY, et al. FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. The Journal of Clinical Investigation. 124: 3879-90. PMID 25105367 DOI: 10.1172/Jci75539  0.468
2014 Zolla-Pazner S. A critical question for HIV vaccine development: which antibodies to induce? Science (New York, N.Y.). 345: 167-8. PMID 25013066 DOI: 10.1126/Science.1256526  0.521
2014 Gartland AJ, Li S, McNevin J, Tomaras GD, Gottardo R, Janes H, Fong Y, Morris D, Geraghty DE, Kijak GH, Edlefsen PT, Frahm N, Larsen BB, Tovanabutra S, Sanders-Buell E, ... ... Zolla-Pazner S, et al. Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial. Journal of Virology. 88: 8242-55. PMID 24829343 DOI: 10.1128/Jvi.01164-14  0.447
2014 Ryndak MB, Singh KK, Peng Z, Zolla-Pazner S, Li H, Meng L, Laal S. Transcriptional profiling of Mycobacterium tuberculosis replicating ex vivo in blood from HIV- and HIV+ subjects. Plos One. 9: e94939. PMID 24755630 DOI: 10.1371/Journal.Pone.0094939  0.423
2014 Yates NL, Liao HX, Fong Y, deCamp A, Vandergrift NA, Williams WT, Alam SM, Ferrari G, Yang ZY, Seaton KE, Berman PW, Alpert MD, Evans DT, O'Connell RJ, Francis D, ... ... Zolla-Pazner S, et al. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Science Translational Medicine. 6: 228ra39. PMID 24648342 DOI: 10.1126/Scitranslmed.3007730  0.548
2014 Zolla-Pazner S, deCamp A, Gilbert PB, Williams C, Yates NL, Williams WT, Howington R, Fong Y, Morris DE, Soderberg KA, Irene C, Reichman C, Pinter A, Parks R, Pitisuttithum P, et al. Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. Plos One. 9: e87572. PMID 24504509 DOI: 10.1371/Journal.Pone.0087572  0.581
2014 Spurrier B, Sampson J, Gorny MK, Zolla-Pazner S, Kong XP. Functional implications of the binding mode of a human conformation-dependent V2 monoclonal antibody against HIV. Journal of Virology. 88: 4100-12. PMID 24478429 DOI: 10.1128/Jvi.03153-13  0.574
2014 deCamp A, Hraber P, Bailer RT, Seaman MS, Ochsenbauer C, Kappes J, Gottardo R, Edlefsen P, Self S, Tang H, Greene K, Gao H, Daniell X, Sarzotti-Kelsoe M, Gorny MK, ... Zolla-Pazner S, et al. Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. Journal of Virology. 88: 2489-507. PMID 24352443 DOI: 10.1128/Jvi.02853-13  0.593
2014 Salomon A, Krachmarov C, Lai Z, Honnen W, Zingman BS, Sarlo J, Gorny MK, Zolla-Pazner S, Robinson JE, Pinter A. Specific sequences commonly found in the V3 domain of HIV-1 subtype C isolates affect the overall conformation of native Env and induce a neutralization-resistant phenotype independent of V1/V2 masking. Virology. 448: 363-74. PMID 24314667 DOI: 10.1016/J.Virol.2013.10.007  0.5
2014 Moog C, Dereuddre-Bosquet N, Teillaud JL, Biedma ME, Holl V, Van Ham G, Heyndrickx L, Van Dorsselaer A, Katinger D, Vcelar B, Zolla-Pazner S, Mangeot I, Kelly C, Shattock RJ, Le Grand R. Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques. Mucosal Immunology. 7: 46-56. PMID 23591718 DOI: 10.1038/Mi.2013.23  0.424
2014 Shen G, Upadhyay C, Zhang J, Pan R, Itri V, Zolla-Pazner S, Kong X, Hioe C. P-D10 Rationally Targeted Mutations to Stabilize the Flexible V2 loop Augment Neutralization of Different HIV-1 Isolates by V1V2 Monoclonal Antibodies Jaids Journal of Acquired Immune Deficiency Syndromes. 67: 91. DOI: 10.1097/01.Qai.0000456199.33185.16  0.537
2014 Upadhyay C, Zhang J, Kumar R, Gorny MK, Nadas A, Zolla-Pazner S, Hioe CE, Mayr L. G-103 Masking of the epitopes in the V2 and V3 loops of the HIV-1 envelope are modulated by different mechanisms Jaids Journal of Acquired Immune Deficiency Syndromes. 67: 68. DOI: 10.1097/01.Qai.0000456176.75558.D4  0.509
2014 Courtney C, Mayr L, Nogueira L, Ngai J, Seaman M, Klein F, Nussenzweig M, Nyambi P, Zolla-Pazner S. Investigating Broad Neutralization in HIV-1 Non-B Subtype Infection in Yaoundé, Cameroon. Aids Research and Human Retroviruses. 30. DOI: 10.1089/Aid.2014.5311.Abstract  0.573
2013 Gottardo R, Bailer RT, Korber BT, Gnanakaran S, Phillips J, Shen X, Tomaras GD, Turk E, Imholte G, Eckler L, Wenschuh H, Zerweck J, Greene K, Gao H, Berman PW, ... ... Zolla-Pazner S, et al. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. Plos One. 8: e75665. PMID 24086607 DOI: 10.1371/Journal.Pone.0075665  0.605
2013 Killikelly A, Zhang HT, Spurrier B, Williams C, Gorny MK, Zolla-Pazner S, Kong XP. Thermodynamic signatures of the antigen binding site of mAb 447-52D targeting the third variable region of HIV-1 gp120. Biochemistry. 52: 6249-57. PMID 23944979 DOI: 10.1021/Bi400645E  0.54
2013 Mayr LM, Cohen S, Spurrier B, Kong XP, Zolla-Pazner S. Epitope mapping of conformational V2-specific anti-HIV human monoclonal antibodies reveals an immunodominant site in V2. Plos One. 8: e70859. PMID 23923028 DOI: 10.1371/Journal.Pone.0070859  0.595
2013 Zolla-Pazner S. Saving specimens after Sandy. The New England Journal of Medicine. 368: e27. PMID 23656587 DOI: 10.1056/Nejmp1303024  0.398
2013 Andrabi R, Williams C, Wang XH, Li L, Choudhary AK, Wig N, Biswas A, Luthra K, Nadas A, Seaman MS, Nyambi P, Zolla-Pazner S, Gorny MK. Cross-neutralizing activity of human anti-V3 monoclonal antibodies derived from non-B clade HIV-1 infected individuals. Virology. 439: 81-8. PMID 23466102 DOI: 10.1016/J.Virol.2012.12.010  0.594
2013 Perez LG, Zolla-Pazner S, Montefiori DC. Antibody-DEPENDENT, FcγRI-mediated neutralization of HIV-1 in TZM-bl cells occurs independently of phagocytosis. Journal of Virology. 87: 5287-90. PMID 23408628 DOI: 10.1128/Jvi.00278-13  0.557
2013 Zolla-Pazner S, deCamp AC, Cardozo T, Karasavvas N, Gottardo R, Williams C, Morris DE, Tomaras G, Rao M, Billings E, Berman P, Shen X, Andrews C, O'Connell RJ, Ngauy V, et al. Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. Plos One. 8: e53629. PMID 23349725 DOI: 10.1371/Journal.Pone.0053629  0.61
2013 Liao HX, Bonsignori M, Alam SM, McLellan JS, Tomaras GD, Moody MA, Kozink DM, Hwang KK, Chen X, Tsao CY, Liu P, Lu X, Parks RJ, Montefiori DC, Ferrari G, ... ... Zolla-Pazner S, et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity. 38: 176-86. PMID 23313589 DOI: 10.1016/J.Immuni.2012.11.011  0.608
2013 Alam SM, Liao HX, Tomaras GD, Bonsignori M, Tsao CY, Hwang KK, Chen H, Lloyd KE, Bowman C, Sutherland L, Jeffries TL, Kozink DM, Stewart S, Anasti K, Jaeger FH, ... ... Zolla-Pazner S, et al. Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion. Journal of Virology. 87: 1554-68. PMID 23175357 DOI: 10.1128/Jvi.00718-12  0.486
2013 O'Connell O, Repik A, Reeves JD, Gonzalez-Perez MP, Quitadamo B, Anton ED, Duenas-Decamp M, Peters P, Lin R, Zolla-Pazner S, Corti D, Wallace A, Wang S, Kong XP, Lu S, et al. Efficiency of bridging-sheet recruitment explains HIV-1 R5 envelope glycoprotein sensitivity to soluble CD4 and macrophage tropism. Journal of Virology. 87: 187-98. PMID 23055568 DOI: 10.1128/Jvi.01834-12  0.446
2013 Zolla-Pazner S, Liao H, Haynes B, Gorny MK, Kong X. E104 Identification of Three Distinct Epitope Regions in the V2 Portion of gp120 Journal of Acquired Immune Deficiency Syndromes. 62. DOI: 10.1097/01.Qai.0000429241.32158.3C  0.368
2012 Yu X, Gilbert PB, Hioe CE, Zolla-Pazner S, Self SG. Statistical approaches to analyzing HIV-1 neutralizing antibody assay data. Statistics in Biopharmaceutical Research. 4: 1-13. PMID 24660049 DOI: 10.1080/19466315.2011.633860  0.427
2012 Li L, Wang XH, Banerjee S, Volsky B, Williams C, Moody MA, Zolla-Pazner S, Gorny MK. Clonal analysis of human anti-V3 monoclonal antibodies selected by a V3 tetramer. Human Antibodies. 21: 65-73. PMID 23549023 DOI: 10.3233/Hab-130264  0.61
2012 Karasavvas N, Billings E, Rao M, Williams C, Zolla-Pazner S, Bailer RT, Koup RA, Madnote S, Arworn D, Shen X, Tomaras GD, Currier JR, Jiang M, Magaret C, Andrews C, et al. The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. Aids Research and Human Retroviruses. 28: 1444-57. PMID 23035746 DOI: 10.1089/Aid.2012.0103  0.624
2012 Li L, Wang XH, Banerjee S, Volsky B, Williams C, Virland D, Nadas A, Seaman MS, Chen X, Spearman P, Zolla-Pazner S, Gorny MK. Different pattern of immunoglobulin gene usage by HIV-1 compared to non-HIV-1 antibodies derived from the same infected subject. Plos One. 7: e39534. PMID 22761815 DOI: 10.1371/Journal.Pone.0039534  0.607
2012 Almond D, Krachmarov C, Swetnam J, Zolla-Pazner S, Cardozo T. Resistance of Subtype C HIV-1 Strains to Anti-V3 Loop Antibodies. Advances in Virology. 2012: 803535. PMID 22548061 DOI: 10.1155/2012/803535  0.588
2012 Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. The New England Journal of Medicine. 366: 1275-86. PMID 22475592 DOI: 10.1056/Nejmoa1113425  0.522
2012 Dadachova E, Kitchen SG, Bristol G, Baldwin GC, Revskaya E, Empig C, Thornton GB, Gorny MK, Zolla-Pazner S, Casadevall A. Pre-clinical evaluation of a 213Bi-labeled 2556 antibody to HIV-1 gp41 glycoprotein in HIV-1 mouse models as a reagent for HIV eradication. Plos One. 7: e31866. PMID 22427811 DOI: 10.1371/Journal.Pone.0031866  0.599
2012 Gorny MK, Pan R, Williams C, Wang XH, Volsky B, O'Neal T, Spurrier B, Sampson JM, Li L, Seaman MS, Kong XP, Zolla-Pazner S. Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals. Virology. 427: 198-207. PMID 22402248 DOI: 10.1016/J.Virol.2012.02.003  0.618
2012 Dueñas-Decamp MJ, O'Connell OJ, Corti D, Zolla-Pazner S, Clapham PR. The W100 pocket on HIV-1 gp120 penetrated by b12 is not a target for other CD4bs monoclonal antibodies. Retrovirology. 9: 9. PMID 22284192 DOI: 10.1186/1742-4690-9-9  0.575
2012 Sampson J, Killikelly A, Zhang H, Gorny M, Zolla-Pazner S, Kong X. High-resolution crystal structure of the Fv of quaternary neutralizing epitope mAb 2909 reveals atomic details of its antigen-binding site Retrovirology. 9: 79. DOI: 10.1186/1742-4690-9-S2-P79  0.316
2012 Rao M, Karasavvas N, Pinter A, Liao H, Bonsignori M, Mathieson B, Zolla-Pazner S, Haynes B, Michael N, Kim J, Alving C, Peachman K. Detection of antibodies to the α4β7 integrin binding site on HIV-1 gp120 V2 loop using a novel cell adhesion assay Retrovirology. 9. DOI: 10.1186/1742-4690-9-S2-P71  0.591
2012 Spurrier B, Pan R, Sampson J, Williams C, Gorny M, Zolla-Pazner S, Kong X. Crystal structure analysis of anti-V2 mAb 2158 suggests a conformational epitope involving an N-linked glycan Retrovirology. 9: 70. DOI: 10.1186/1742-4690-9-S2-P70  0.515
2012 Killikelly A, Zhang H, Spurrier B, Williams C, Gorny M, Zolla-Pazner S, Kong X. Biophysical dissection of the antigen-antibody interaction of the broadly reactive anti-V3 human mAb 447-52D Retrovirology. 9: 67. DOI: 10.1186/1742-4690-9-S2-P67  0.541
2012 Manhas S, Clark B, Gorny M, Zolla-Pazner S, Pantophlet R. Residue 315 regulates V3 exposure and V3 antibody recognition on HIV subtype B and C viruses Retrovirology. 9: 54. DOI: 10.1186/1742-4690-9-S2-P54  0.497
2012 Chiu Y, Jiang X, Kumar R, Hioe C, Zolla-Pazner S, Kong X. Skin tattooing as an effective tool for delivering DNA and protein vaccine immunogens Retrovirology. 9: 338. DOI: 10.1186/1742-4690-9-S2-P338  0.382
2012 Polonis V, Wieczorek L, Kalyanaraman V, Matyas G, Whitney S, Williams C, Tovanabutra S, Sanders-Buell E, Wesberry M, Ochsenbauer C, Chenine A, Rao M, Tong T, Alving C, Cheng H, ... Zolla-Pazner S, et al. Antigenicity and immunogenicity of a novel, acute HIV-1 Tanzanian subtype C gp145 envelope protein for clinical development Retrovirology. 9: 323. DOI: 10.1186/1742-4690-9-S2-P323  0.559
2012 O'Connell O, Repik A, Reeves J, Gonzalez-Perez M, Quitadamo B, Duenas-Decamp M, Peters P, Lin R, Anton E, Zolla-Pazner S, Corti D, Wallace A, Wang S, Kong X, Lu S, et al. The efficiency of bridging sheet recruitment determines HIV-1 R5 envelope sensitivity to soluble CD4 and macrophage tropism Retrovirology. 9: 141. DOI: 10.1186/1742-4690-9-S2-P141  0.433
2012 Moog C, Dereuddre-Bosquet N, Biedma M, Schmidt S, Decoville T, Mangeot I, Zolla-Pazner S, Vcelar B, Katinger D, Holl V, Grand RL. Non-neutralizing IgG anti-PID antibodies decreased viral load following high dose vaginal challenge of non-human primates Retrovirology. 9: 1-1. DOI: 10.1186/1742-4690-9-S2-O38  0.478
2012 Liao L, Bonsignori M, Hwang K, Moody A, Park R, Crawford S, Chen H, Jeffries T, Cooper M, Lu X, De R, Karasavvas N, Rerks-Ngarm S, Nitayaphan S, Kaewkungwal J, ... ... Zolla-Pazner S, et al. Design of an HIV Env antigen that binds with high affinity to antibodies against linear, conformational and broadly neutralizing epitopes within V1/V2 Retrovirology. 9. DOI: 10.1186/1742-4690-9-S2-O31  0.476
2012 Zolla-Pazner S, Williams C, deCamp A, Morris D, Haynes B, Kim J, Michael N, Rao M. 114 Role of Vaccine-induced V2 Antibodies in Protection From HIV Infection of Recipients in the RV144 Clinical Vaccine Trial Jaids Journal of Acquired Immune Deficiency Syndromes. 59: 46. DOI: 10.1097/01.Qai.0000413733.06987.08  0.586
2011 Gorny MK, Sampson J, Li H, Jiang X, Totrov M, Wang XH, Williams C, O'Neal T, Volsky B, Li L, Cardozo T, Nyambi P, Zolla-Pazner S, Kong XP. Human anti-V3 HIV-1 monoclonal antibodies encoded by the VH5-51/VL lambda genes define a conserved antigenic structure. Plos One. 6: e27780. PMID 22164215 DOI: 10.1371/Journal.Pone.0027780  0.526
2011 Shmelkov E, Nadas A, Swetnam J, Zolla-Pazner S, Cardozo T. Indirect detection of an epitope-specific response to HIV-1 gp120 immunization in human subjects. Plos One. 6: e27279. PMID 22076145 DOI: 10.1371/Journal.Pone.0027279  0.563
2011 Ringe R, Sharma D, Zolla-Pazner S, Phogat S, Risbud A, Thakar M, Paranjape R, Bhattacharya J. A single amino acid substitution in the C4 region in gp120 confers enhanced neutralization of HIV-1 by modulating CD4 binding sites and V3 loop. Virology. 418: 123-32. PMID 21851958 DOI: 10.1016/J.Virol.2011.07.015  0.591
2011 Krachmarov C, Lai Z, Honnen WJ, Salomon A, Gorny MK, Zolla-Pazner S, Robinson J, Pinter A. Characterization of structural features and diversity of variable-region determinants of related quaternary epitopes recognized by human and rhesus macaque monoclonal antibodies possessing unusually potent neutralizing activities. Journal of Virology. 85: 10730-40. PMID 21835798 DOI: 10.1128/Jvi.00365-11  0.506
2011 Zolla-Pazner S, Kong XP, Jiang X, Cardozo T, Nádas A, Cohen S, Totrov M, Seaman MS, Wang S, Lu S. Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA. Journal of Virology. 85: 9887-98. PMID 21795338 DOI: 10.1128/Jvi.05086-11  0.534
2011 Spurrier B, Sampson JM, Totrov M, Li H, O'Neal T, Williams C, Robinson J, Gorny MK, Zolla-Pazner S, Kong XP. Structural analysis of human and macaque mAbs 2909 and 2.5B: implications for the configuration of the quaternary neutralizing epitope of HIV-1 gp120. Structure (London, England : 1993). 19: 691-9. PMID 21565703 DOI: 10.1016/J.Str.2011.02.012  0.61
2011 Wu X, Changela A, O'Dell S, Schmidt SD, Pancera M, Yang Y, Zhang B, Gorny MK, Phogat S, Robinson JE, Stamatatos L, Zolla-Pazner S, Kwong PD, Mascola JR. Immunotypes of a quaternary site of HIV-1 vulnerability and their recognition by antibodies. Journal of Virology. 85: 4578-85. PMID 21325411 DOI: 10.1128/Jvi.02585-10  0.609
2011 Agarwal A, Hioe CE, Swetnam J, Zolla-Pazner S, Cardozo T. Quantitative assessment of masking of neutralization epitopes in HIV-1. Vaccine. 29: 6736-41. PMID 21216319 DOI: 10.1016/J.Vaccine.2010.12.052  0.617
2011 Changela A, Wu X, Yang Y, Zhang B, Zhu J, Nardone GA, O'Dell S, Pancera M, Gorny MK, Phogat S, Robinson JE, Stamatatos L, Zolla-Pazner S, Mascola JR, Kwong PD. Crystal structure of human antibody 2909 reveals conserved features of quaternary structure-specific antibodies that potently neutralize HIV-1. Journal of Virology. 85: 2524-35. PMID 21191009 DOI: 10.1128/Jvi.02335-10  0.559
2011 Musich T, Peters PJ, Duenas-Decamp MJ, Gonzalez-Perez MP, Robinson J, Zolla-Pazner S, Ball JK, Luzuriaga K, Clapham PR. A conserved determinant in the V1 loop of HIV-1 modulates the V3 loop to prime low CD4 use and macrophage infection. Journal of Virology. 85: 2397-405. PMID 21159865 DOI: 10.1128/Jvi.02187-10  0.41
2011 Dennison SM, Anasti K, Scearce RM, Sutherland L, Parks R, Xia SM, Liao HX, Gorny MK, Zolla-Pazner S, Haynes BF, Alam SM. Nonneutralizing HIV-1 gp41 envelope cluster II human monoclonal antibodies show polyreactivity for binding to phospholipids and protein autoantigens. Journal of Virology. 85: 1340-7. PMID 21106741 DOI: 10.1128/Jvi.01680-10  0.5
2011 Agarwal A, Oronsaye E, Nadas A, Zolla-Pazner S, Cardozo T. CCR5/CXCR4 discriminating sites in the HIV-1 Gp120 core 2011 Acm Conference On Bioinformatics, Computational Biology and Biomedicine, Bcb 2011. 519-521. DOI: 10.1145/2147805.2147888  0.362
2011 Zolla-Pazner S. 164 Using Epitopes Recognized by Monoclonal Antibodies as Vaccine Templates Journal of Acquired Immune Deficiency Syndromes. 56: 69. DOI: 10.1097/01.Qai.0000397351.15427.4E  0.429
2011 Totrov M, Jiang X, Kong XP, Cohen S, Krachmarov C, Salomon A, Williams C, Seaman MS, Abagyan R, Cardozo T, Gorny MK, Wang S, Lu S, Pinter A, Zolla-Pazner S. Corrigendum to Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold" [Virology 351 (2010) 513-523] Virology. 409: 360. DOI: 10.1016/J.Virol.2010.11.003  0.531
2010 Swetnam J, Shmelkov E, Zolla-Pazner S, Cardozo T. Comparative magnitude of cross-strain conservation of HIV variable loop neutralization epitopes. Plos One. 5: e15994. PMID 21209919 DOI: 10.1371/Journal.Pone.0015994  0.546
2010 Frey G, Chen J, Rits-Volloch S, Freeman MM, Zolla-Pazner S, Chen B. Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies. Nature Structural & Molecular Biology. 17: 1486-91. PMID 21076402 DOI: 10.1038/Nsmb.1950  0.58
2010 Totrov M, Jiang X, Kong XP, Cohen S, Krachmarov C, Salomon A, Williams C, Seaman MS, Abagyan R, Cardozo T, Gorny MK, Wang S, Lu S, Pinter A, Zolla-Pazner S. Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold. Virology. 405: 513-23. PMID 20663531 DOI: 10.1016/J.Virol.2010.06.027  0.571
2010 Jiang X, Burke V, Totrov M, Williams C, Cardozo T, Gorny MK, Zolla-Pazner S, Kong XP. Conserved structural elements in the V3 crown of HIV-1 gp120. Nature Structural & Molecular Biology. 17: 955-61. PMID 20622876 DOI: 10.1038/Nsmb.1861  0.58
2010 Zolla-Pazner S, Cardozo T. Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. Nature Reviews. Immunology. 10: 527-35. PMID 20577269 DOI: 10.1038/Nri2801  0.567
2010 Almond D, Kimura T, Kong X, Swetnam J, Zolla-Pazner S, Cardozo T. Structural conservation predominates over sequence variability in the crown of HIV type 1's V3 loop. Aids Research and Human Retroviruses. 26: 717-23. PMID 20560796 DOI: 10.1089/Aid.2009.0254  0.539
2010 Hager-Braun C, Hochleitner EO, Gorny MK, Zolla-Pazner S, Bienstock RJ, Tomer KB. Characterization of a discontinuous epitope of the HIV envelope protein gp120 recognized by a human monoclonal antibody using chemical modification and mass spectrometric analysis. Journal of the American Society For Mass Spectrometry. 21: 1687-98. PMID 20434359 DOI: 10.1016/J.Jasms.2010.03.031  0.452
2010 Hioe CE, Wrin T, Seaman MS, Yu X, Wood B, Self S, Williams C, Gorny MK, Zolla-Pazner S. Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes. Plos One. 5: e10254. PMID 20421997 DOI: 10.1371/Journal.Pone.0010254  0.63
2010 Robinson JE, Franco K, Elliott DH, Maher MJ, Reyna A, Montefiori DC, Zolla-Pazner S, Gorny MK, Kraft Z, Stamatatos L. Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4. Journal of Virology. 84: 3443-53. PMID 20106929 DOI: 10.1128/Jvi.02617-09  0.641
2009 Burke V, Williams C, Sukumaran M, Kim SS, Li H, Wang XH, Gorny MK, Zolla-Pazner S, Kong XP. Structural basis of the cross-reactivity of genetically related human anti-HIV-1 mAbs: implications for design of V3-based immunogens. Structure (London, England : 1993). 17: 1538-46. PMID 19913488 DOI: 10.1016/J.Str.2009.09.012  0.548
2009 Zolla-Pazner S, Cohen S, Pinter A, Krachmarov C, Wrin T, Wang S, Lu S. Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope. Virology. 392: 82-93. PMID 19632700 DOI: 10.1016/J.Virol.2009.05.039  0.551
2009 Kimura T, Wang XH, Williams C, Zolla-Pazner S, Gorny MK. Human monoclonal antibody 2909 binds to pseudovirions expressing trimers but not monomeric HIV-1 envelope proteins. Human Antibodies. 18: 35-40. PMID 19478397 DOI: 10.3233/Hab-2009-0200  0.597
2009 Cardozo T, Swetnam J, Pinter A, Krachmarov C, Nadas A, Almond D, Zolla-Pazner S. Worldwide distribution of HIV type 1 epitopes recognized by human anti-V3 monoclonal antibodies. Aids Research and Human Retroviruses. 25: 441-50. PMID 19320565 DOI: 10.1089/Aid.2008.0188  0.643
2009 Yuan W, Li X, Kasterka M, Gorny MK, Zolla-Pazner S, Sodroski J. Oligomer-specific conformations of the human immunodeficiency virus (HIV-1) gp41 envelope glycoprotein ectodomain recognized by human monoclonal antibodies. Aids Research and Human Retroviruses. 25: 319-28. PMID 19292593 DOI: 10.1089/Aid.2008.0213  0.528
2009 Fenyö EM, Heath A, Dispinseri S, Holmes H, Lusso P, Zolla-Pazner S, Donners H, Heyndrickx L, Alcami J, Bongertz V, Jassoy C, Malnati M, Montefiori D, Moog C, Morris L, et al. International network for comparison of HIV neutralization assays: the NeutNet report. Plos One. 4: e4505. PMID 19229336 DOI: 10.1371/journal.pone.0004505  0.458
2009 Gorny MK, Wang XH, Williams C, Volsky B, Revesz K, Witover B, Burda S, Urbanski M, Nyambi P, Krachmarov C, Pinter A, Zolla-Pazner S, Nadas A. Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1. Molecular Immunology. 46: 917-26. PMID 18952295 DOI: 10.1016/J.Molimm.2008.09.005  0.519
2009 Zolla-Pazner S, Wrin T, Seaman MS, Yu X, Wood B, Self S, Hioe CE. P04-55 LB. Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes Retrovirology. 6: P395. DOI: 10.1186/1742-4690-6-S3-P395  0.509
2009 Gorny M, Williams C, O'Neal T, Choudhary A, Luthra K, Wood B, Seaman, Nyambi P, Zolla-Pazner S. P04-10. Neutralization of Tier 1 and Tier 2 pseudoviruses by human anti-V3 monoclonal antibodies. Retrovirology. 6: 38. DOI: 10.1186/1742-4690-6-S3-P38  0.456
2009 Swetnam J, Zolla-Pazner S, Cardozo TJ. P20-09. Worldwide epitope prevalence of crystallographically resolved anti-V3 antibodies Retrovirology. 6: P379. DOI: 10.1186/1742-4690-6-S3-P379  0.447
2009 Zolla-Pazner S, Kong X, Cardozo T, Hioe C, Cohen S, Jiang X, Gorny MK, Totrov M, Pinter A, Krachmarov C, Seaman MS, Wang S, Lu S. P04-09. Induction of cross-clade neutralizing antibodies with a prime/boost vaccine strategy focused on a neutralizing epitope Retrovirology. 6: P37. DOI: 10.1186/1742-4690-6-S3-P37  0.497
2009 Almond D, Kimura T, Kong X, Swetnam J, Zolla-Pazner S, Cardozo T. P19-21. Sequence variability in the crown of the V3 loop of the HIV-1 envelope is clustered within a small 3D structural zone Retrovirology. 6: P341. DOI: 10.1186/1742-4690-6-S3-P341  0.439
2009 Totrov M, Jiang X, Kong X, Cohen S, Krachmarov C, Williams C, Cardozo T, Gorny M, Wang S, Lu S, Pinter A, Zolla-Pazner S. P12-13. Structure-guided design and immunological characterization of immunogen constructs presenting the HIV-1 gp120 V3 loop on a CTB scaffold Retrovirology. 6: P179. DOI: 10.1186/1742-4690-6-S3-P179  0.583
2009 Zolla-Pazner S, Cohen S, Krachmarov C, Pinter A, Wang S, Lu S. 171 Induction of Cross-clade Neutralizing Antibodies in Rabbits Using a DNA Prime/Protein Boost Immunization Regimen Jaids Journal of Acquired Immune Deficiency Syndromes. 51: 1. DOI: 10.1097/01.Qai.0000351131.71782.2E  0.374
2009 Gorny MK, Williams C, O'Neal T, Choudhary AK, Luthra K, Wood B, Seaman MS, Nyambi P, Zolla-Pazner S. P04-10. Neutralization of Tier 1 and Tier 2 pseudoviruses by human anti-V3 monoclonal antibodies Retrovirology. 6.  0.351
2008 Wu X, Sambor A, Nason MC, Yang ZY, Wu L, Zolla-Pazner S, Nabel GJ, Mascola JR. Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses. Virology. 380: 285-95. PMID 18804254 DOI: 10.1016/J.Virol.2008.07.007  0.58
2008 Dhillon AK, Stanfield RL, Gorny MK, Williams C, Zolla-Pazner S, Wilson IA. Structure determination of an anti-HIV-1 Fab 447-52D-peptide complex from an epitaxially twinned data set Acta Crystallographica Section D: Biological Crystallography. 64: 792-802. PMID 18566514 DOI: 10.1107/S0907444908013978  0.503
2008 Polonis VR, Brown BK, Rosa Borges A, Zolla-Pazner S, Dimitrov DS, Zhang MY, Barnett SW, Ruprecht RM, Scarlatti G, Fenyö EM, Montefiori DC, McCutchan FE, Michael NL. Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology. 375: 315-20. PMID 18367229 DOI: 10.1016/J.Virol.2008.02.007  0.511
2008 Zolla-Pazner S, Cohen SS, Krachmarov C, Wang S, Pinter A, Lu S. Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope. Virology. 372: 233-46. PMID 18061228 DOI: 10.1016/J.Virol.2007.09.024  0.518
2008 Alam SM, Scearce RM, Parks RJ, Plonk K, Plonk SG, Sutherland LL, Gorny MK, Zolla-Pazner S, Vanleeuwen S, Moody MA, Xia SM, Montefiori DC, Tomaras GD, Weinhold KJ, Karim SA, et al. Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection. Journal of Virology. 82: 115-25. PMID 17942537 DOI: 10.1128/Jvi.00927-07  0.613
2007 Cardozo T, Kimura T, Philpott S, Weiser B, Burger H, Zolla-Pazner S. Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. Aids Research and Human Retroviruses. 23: 415-26. PMID 17411375 DOI: 10.1089/Aid.2006.0130  0.419
2007 Honnen WJ, Krachmarov C, Kayman SC, Gorny MK, Zolla-Pazner S, Pinter A. Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence Journal of Virology. 81: 1424-1432. PMID 17121806 DOI: 10.1128/Jvi.02054-06  0.542
2006 Dadachova E, Patel MC, Toussi S, Apostolidis C, Morgenstern A, Brechbiel MW, Gorny MK, Zolla-Pazner S, Casadevall A, Goldstein H. Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins. Plos Medicine. 3: e427. PMID 17090209 DOI: 10.1371/Journal.Pmed.0030427  0.52
2006 Khurana S, Needham J, Park S, Mathieson B, Busch MP, Nemo G, Nyambi P, Zolla-Pazner S, Laal S, Mulenga J, Chomba E, Hunter E, Allen S, McIntyre J, Hewlett I, et al. Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: utility for detection of diverse HIV-1 subtypes. Journal of Acquired Immune Deficiency Syndromes (1999). 43: 304-12. PMID 17019363 DOI: 10.1097/01.Qai.0000242465.50947.5F  0.57
2006 Williams JG, Tomer KB, Hioe CE, Zolla-Pazner S, Norris PJ. The antigenic determinants on HIV p24 for CD4+ T cell inhibiting antibodies as determined by limited proteolysis, chemical modification, and mass spectrometry. Journal of the American Society For Mass Spectrometry. 17: 1560-9. PMID 16875837 DOI: 10.1016/J.Jasms.2006.06.011  0.524
2006 Gorny MK, Zolla-Pazner S. Immunoprophylaxis against mother-to-child transmission of HIV-1. Plos Medicine. 3: e259. PMID 16842019 DOI: 10.1371/Journal.Pmed.0030259  0.413
2006 Felsövályi K, Nádas A, Zolla-Pazner S, Cardozo T. Distinct sequence patterns characterize the V3 region of HIV type 1 gp120 from subtypes A and C. Aids Research and Human Retroviruses. 22: 703-8. PMID 16831095 DOI: 10.1089/Aid.2006.22.703  0.495
2006 Krachmarov CP, Honnen WJ, Kayman SC, Gorny MK, Zolla-Pazner S, Pinter A. Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1. Journal of Virology. 80: 7127-35. PMID 16809318 DOI: 10.1128/Jvi.02619-05  0.493
2006 Gorny MK, Williams C, Volsky B, Revesz K, Wang XH, Burda S, Kimura T, Konings FA, Nádas A, Anyangwe CA, Nyambi P, Krachmarov C, Pinter A, Zolla-Pazner S. Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1. Journal of Virology. 80: 6865-72. PMID 16809292 DOI: 10.1128/Jvi.02202-05  0.802
2006 Holl V, Peressin M, Decoville T, Schmidt S, Zolla-Pazner S, Aubertin AM, Moog C. Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. Journal of Virology. 80: 6177-81. PMID 16731957 DOI: 10.1128/Jvi.02625-05  0.583
2006 Stanfield RL, Gorny MK, Zolla-Pazner S, Wilson IA. Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity. Journal of Virology. 80: 6093-105. PMID 16731948 DOI: 10.1128/Jvi.00205-06  0.56
2006 Holl V, Peressin M, Schmidt S, Decoville T, Zolla-Pazner S, Aubertin AM, Moog C. Efficient inhibition of HIV-1 replication in human immature monocyte-derived dendritic cells by purified anti-HIV-1 IgG without induction of maturation. Blood. 107: 4466-74. PMID 16469871 DOI: 10.1182/Blood-2005-08-3490  0.574
2006 Zolla-Pazner S, Sharpe-Cohen S, Krachmarov C, Wang S, Pinter A, Lu S. Focusing the immune response on the V3 loop of HIV-1 gp120 induces cross-clade neutralizing Retrovirology. 3. DOI: 10.1186/1742-4690-3-S1-S23  0.503
2005 Zolla-Pazner S. Improving on nature: focusing the immune response on the V3 loop. Human Antibodies. 14: 69-72. PMID 16720976 DOI: 10.3233/Hab-2005-143-403  0.612
2005 de Parseval A, Bobardt MD, Chatterji A, Chatterji U, Elder JH, David G, Zolla-Pazner S, Farzan M, Lee TH, Gallay PA. A highly conserved arginine in gp120 governs HIV-1 binding to both syndecans and CCR5 via sulfated motifs. The Journal of Biological Chemistry. 280: 39493-504. PMID 16157597 DOI: 10.1074/Jbc.M504233200  0.537
2005 Louder MK, Sambor A, Chertova E, Hunte T, Barrett S, Ojong F, Sanders-Buell E, Zolla-Pazner S, McCutchan FE, Roser JD, Gabuzda D, Lifson JD, Mascola JR. HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensitivity. Virology. 339: 226-38. PMID 16005039 DOI: 10.1016/J.Virol.2005.06.003  0.602
2005 Pinter A, Honnen WJ, D'Agostino P, Gorny MK, Zolla-Pazner S, Kayman SC. The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates. Journal of Virology. 79: 6909-17. PMID 15890930 DOI: 10.1128/Jvi.79.11.6909-6917.2005  0.522
2005 Rosen O, Chill J, Sharon M, Kessler N, Mester B, Zolla-Pazner S, Anglister J. Induced fit in HIV-neutralizing antibody complexes: evidence for alternative conformations of the gp120 V3 loop and the molecular basis for broad neutralization. Biochemistry. 44: 7250-8. PMID 15882063 DOI: 10.1021/Bi047387T  0.511
2005 Gorny MK, Stamatatos L, Volsky B, Revesz K, Williams C, Wang XH, Cohen S, Staudinger R, Zolla-Pazner S. Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. Journal of Virology. 79: 5232-7. PMID 15795308 DOI: 10.1128/Jvi.79.8.5232-5237.2005  0.626
2005 Someya K, Cecilia D, Ami Y, Nakasone T, Matsuo K, Burda S, Yamamoto H, Yoshino N, Kaizu M, Ando S, Okuda K, Zolla-Pazner S, Yamazaki S, Yamamoto N, Honda M. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif. Journal of Virology. 79: 1452-62. PMID 15650171 DOI: 10.1128/Jvi.79.3.1452-1462.2005  0.59
2005 Krachmarov C, Pinter A, Honnen WJ, Gorny MK, Nyambi PN, Zolla-Pazner S, Kayman SC. Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking. Journal of Virology. 79: 780-90. PMID 15613306 DOI: 10.1128/Jvi.79.2.780-790.2005  0.539
2004 Zolla-Pazner S, Zhong P, Revesz K, Volsky B, Williams C, Nyambi P, Gorny MK. The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1. Aids Research and Human Retroviruses. 20: 1254-8. PMID 15588347 DOI: 10.1089/Aid.2004.20.1254  0.583
2004 Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, Stiegler G, Kunert R, Zolla-Pazner S, Katinger H, Petropoulos CJ, Burton DR. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. Journal of Virology. 78: 13232-52. PMID 15542675 DOI: 10.1128/Jvi.78.23.13232-13252.2004  0.575
2004 Yang X, Tomov V, Kurteva S, Wang L, Ren X, Gorny MK, Zolla-Pazner S, Sodroski J. Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1 Journal of Virology. 78: 12975-12986. PMID 15542649 DOI: 10.1128/Jvi.78.23.12975-12986.2004  0.622
2004 Achkar JM, Burda ST, Konings FA, Urbanski MM, Williams CA, Seifen D, Kahirimbanyi MN, Vogler M, Parta M, Lupatkin HC, Zolla-Pazner S, Nyambi PN. Infection with HIV type 1 group M non-B subtypes in individuals living in New York City. Journal of Acquired Immune Deficiency Syndromes (1999). 36: 835-44. PMID 15213568 DOI: 10.1097/00126334-200407010-00011  0.799
2004 Pinter A, Honnen WJ, He Y, Gorny MK, Zolla-Pazner S, Kayman SC. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. Journal of Virology. 78: 5205-15. PMID 15113902 DOI: 10.1128/Jvi.78.10.5205-5215.2004  0.592
2004 Zolla-Pazner S. Identifying epitopes of HIV-1 that induce protective antibodies Nature Reviews Immunology. 4: 199-210. PMID 15039757 DOI: 10.1038/Nri1307  0.564
2004 Nádas A, Zhong P, Burda S, Zekeng L, Urbanski M, Gorny MK, Zolla-Pazner S, Nyambi PN. Defining Human Immunodeficiency Virus (HIV) Type 1 Immunotypes with Six Human Monoclonal Antibodies Aids Research and Human Retroviruses. 20: 55-65. PMID 15000699 DOI: 10.1089/088922204322749503  0.616
2004 Gorny MK, Revesz K, Williams C, Volsky B, Louder MK, Anyangwe CA, Krachmarov C, Kayman SC, Pinter A, Nadas A, Nyambi PN, Mascola JR, Zolla-Pazner S. The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope. Journal of Virology. 78: 2394-404. PMID 14963135 DOI: 10.1128/Jvi.78.5.2394-2404.2004  0.522
2004 Stanfield RL, Gorny MK, Williams C, Zolla-Pazner S, Wilson IA. Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. Structure (London, England : 1993). 12: 193-204. PMID 14962380 DOI: 10.1016/J.Str.2004.01.003  0.551
2003 Zhong P, Burda S, Konings F, Urbanski M, Ma L, Zekeng L, Ewane L, Agyingi L, Agwara M, Saa, Ze E A, Kinge T, Zolla-Pazner S, Nyambi P. Genetic and Biological Properties of HIV Type 1 Isolates Prevalent in Villagers of the Cameroon Equatorial Rain Forests and Grass Fields: Further Evidence of Broad HIV Type 1 Genetic Diversity Aids Research and Human Retroviruses. 19: 1167-1178. PMID 14717120 DOI: 10.1089/088922203771881284  0.501
2003 Singh KK, Dong Y, Hinds L, Keen MA, Belisle JT, Zolla-Pazner S, Achkar JM, Nadas AJ, Arora VK, Laal S. Combined use of serum and urinary antibody for diagnosis of tuberculosis. The Journal of Infectious Diseases. 188: 371-7. PMID 12870118 DOI: 10.1086/376532  0.393
2003 Kessler N, Zvi A, Ji M, Sharon M, Rosen O, Levy R, Gorny M, Zolla-Pazner S, Anglister J. Expression, purification, and isotope labeling of the Fv of the human HIV-1 neutralizing antibody 447-52D for NMR studies. Protein Expression and Purification. 29: 291-303. PMID 12767822 DOI: 10.1016/S1046-5928(03)00047-0  0.442
2003 Sharon M, Kessler N, Levy R, Zolla-Pazner S, Görlach M, Anglister J. Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity. Structure (London, England : 1993). 11: 225-36. PMID 12575942 DOI: 10.1016/S0969-2126(03)00011-X  0.443
2002 Nyambi P, Zekeng L, Kenfack H, Tongo M, Nanfack A, Nkombe I, Ndonko F, Shang J, Burda S, Mbah H, Agyingi L, Zhong P, Nádas A, Zolla-Pazner S, Marmor M. HIV infection in rural villages of Cameroon Journal of Acquired Immune Deficiency Syndromes. 31: 506-513. PMID 12473839 DOI: 10.1097/00126334-200212150-00008  0.489
2002 Zhong P, Burda S, Urbanski M, Kenfack H, Tongo M, Heyndrickx L, Nanfack A, Shang J, Agyingi L, Zolla-Pazner S, Zekeng L, Nyambi P. HIV type 1 group M clades infecting subjects from rural villages in equatorial rain forests of Cameroon Journal of Acquired Immune Deficiency Syndromes. 31: 495-505. PMID 12473838 DOI: 10.1097/00126334-200212150-00007  0.44
2002 Gorny MK, Williams C, Volsky B, Revesz K, Cohen S, Polonis VR, Honnen WJ, Kayman SC, Krachmarov C, Pinter A, Zolla-Pazner S. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. Journal of Virology. 76: 9035-45. PMID 12186887 DOI: 10.1128/Jvi.76.18.9035-9045.2002  0.571
2002 Chien PC, Cohen S, Kleeberger C, Giorgi J, Phair J, Zolla-Pazner S, Hioe CE. High levels of antibodies to the CD4 binding domain of human immunodeficiency virus type 1 glycoprotein 120 are associated with faster disease progression. The Journal of Infectious Diseases. 186: 205-13. PMID 12134256 DOI: 10.1086/341297  0.536
2002 Golding H, Zaitseva M, De Rosny E, King LR, Manischewitz J, Sidorov I, Gorny MK, Zolla-Pazner S, Dimitrov DS, Weiss CD. Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates Journal of Virology. 76: 6780-6790. PMID 12050391 DOI: 10.1128/Jvi.76.13.6780-6790.2002  0.496
2002 Edwards TG, Wyss S, Reeves JD, Zolla-Pazner S, Hoxie JA, Doms RW, Baribaud F. Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein. Journal of Virology. 76: 2683-91. PMID 11861835 DOI: 10.1128/Jvi.76.6.2683-2691.2002  0.407
2002 Zhang PF, Bouma P, Park EJ, Margolick JB, Robinson JE, Zolla-Pazner S, Flora MN, Quinnan GV. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response. Journal of Virology. 76: 644-55. PMID 11752155 DOI: 10.1128/Jvi.76.2.644-655.2002  0.577
2002 Hager-Braun C, Hochleitner EO, Bienstock R, Gorny MK, Zolla-Pazner S, Tomer KB. Characterization of a discontinuous epitope of the HIV envelope protein gp120 recognized by the monoclonal antibody 559/64-D by chemical modification and mass spectrometric analysis Proceedings 50th Asms Conference On Mass Spectrometry and Allied Topics. 427-428.  0.458
2001 Hioe CE, Tuen M, Chien P.C. J, Jones G, Ratto-Kim S, Norris PJ, Moretto WJ, Nixon DF, Gorny MK, Zolla-Pazner S. Inhibition of human immunodeficiency virus type 1 gp120 presentation to CD4 T cells by antibodies specific for the CD4 binding domain of gp120 Journal of Virology. 75: 10950-10957. PMID 11602735 DOI: 10.1128/Jvi.75.22.10950-10957.2001  0.467
2001 Jeffs SA, Gorny MK, Williams C, Revesz K, Volsky B, Burda S, Wang XH, Bandres J, Zolla-Pazner S, Holmes H. Characterization of human monoclonal antibodies selected with a hypervariable loop-deleted recombinant HIV-1IIIB gp120 Immunology Letters. 79: 209-213. PMID 11600200 DOI: 10.1016/S0165-2478(01)00289-9  0.615
2001 Verrier F, Nádas A, Gorny MK, Zolla-Pazner S. Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6 Journal of Virology. 75: 9177-9186. PMID 11533181 DOI: 10.1128/Jvi.75.19.9177-9186.2001  0.618
2001 Mbah HA, Burda S, Gorny MK, Williams C, Revesz K, Zolla-Pazner S, Nyambi PN. Effect of soluble CD4 on exposure of epitopes on primary, intact, native human immunodeficiency virus type 1 virions of different genetic clades Journal of Virology. 75: 7785-7788. PMID 11462056 DOI: 10.1128/Jvi.75.16.7785-7788.2001  0.445
2001 Barre-Sinoussi F, Berkley S, Bhamarapravati N, Birx D, Bloom B, Carvalheiro J, Ganguly N, Johnston M, Kazatchkine M, Makgoba WM, Monico SM, Nathanson N, Schild G, Wigzell H, Yamasaki S, ... ... Zolla-Pazner S, et al. Approaches to the development of broadly protective HIV vaccines: Challenges posed by the genetic, biological and antigenic variability of HIV-1 Aids. 15: W1-W25. PMID 11371709 DOI: 10.1097/00002030-200104130-00030  0.421
2001 York J, Follis KE, Trahey M, Nyambi PN, Zolla-Pazner S, Nunberg JH. Antibody binding and neutralization of primary and T-cell line-adapted isolates of human immunodeficiency virus type 1 Journal of Virology. 75: 2741-2752. PMID 11222697 DOI: 10.1128/Jvi.75.6.2741-2752.2001  0.6
2000 Nyambi PN, Nadas A, Mbah HA, Burda S, Williams C, Gorny MK, Zolla-Pazner S. Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes Journal of Virology. 74: 10670-10680. PMID 11044111 DOI: 10.1128/Jvi.74.22.10670-10680.2000  0.595
2000 Verrier F, Burda S, Belshe R, Duliege AM, Excler JL, Klein M, Zolla-Pazner S. A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates Journal of Virology. 74: 10025-10033. PMID 11024131 DOI: 10.1128/Jvi.74.21.10025-10033.2000  0.588
2000 Lallos LB, Cecilia D, Fenyö EM, Laal S, Zolla-Pazner S. HIV phenotype correlates with the relative amounts of lymphocyte function-related molecule 1 (LFA-1) and major histocompatibility complex (MHC) class II in the virion envelope Aids. 14: 1523-1531. PMID 10983639 DOI: 10.1097/00002030-200007280-00008  0.374
2000 Achkar JM, Wang XH, Nyambi P, Gorny MK, Zolla-Pazner S, Bandrés JC. Polymerase chain reaction-based assay for antibody-mediated neutralization of HIV-1 reveals a population of nonneutralized virus undetected by conventional p24 assay Journal of Acquired Immune Deficiency Syndromes. 24: 203-210. PMID 10969343 DOI: 10.1097/00126334-200007010-00002  0.624
2000 Taniguchi Y, Zolla-Pazner S, Xu Y, Zhang X, Takeda S, Hattori T. Human monoclonal antibody 98-6 reacts with the fusogenic form of gp41 Virology. 273: 333-340. PMID 10915604 DOI: 10.1006/Viro.2000.0436  0.441
2000 Nyambi PN, Mbah HA, Burda S, Williams C, Gorny MK, Nádas A, Zolla-Pazner S. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M Journal of Virology. 74: 7096-7107. PMID 10888650 DOI: 10.1128/Jvi.74.15.7096-7107.2000  0.571
2000 Samanich KM, Keen MA, Vissa VD, Harder JD, Spencer JS, Belisle JT, Zolla-Pazner S, Laal S. Serodiagnostic potential of culture filtrate antigens of Mycobacterium tuberculosis. Clinical and Diagnostic Laboratory Immunology. 7: 662-8. PMID 10882669 DOI: 10.1128/Cdli.7.4.662-668.2000  0.486
2000 Hioe CE, Jones GJ, Rees AD, Ratto-Kim S, Birx D, Münz C, Gorny MK, Tuen M, Zolla-Pazner S. Anti-CD4-binding domain antibodies complexed with HIV type 1 glycoprotein 120 inhibit CD4+ T cell-proliferative responses to glycoprotein 120 Aids Research and Human Retroviruses. 16: 893-905. PMID 10875615 DOI: 10.1089/08892220050042837  0.456
2000 Gorny MK, Zolla-Pazner S. Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41 Journal of Virology. 74: 6186-6192. PMID 10846104 DOI: 10.1128/Jvi.74.13.6186-6192.2000  0.502
2000 Park EJ, Gorny MK, Zolla-Pazner S, Quinnan GV. A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex Journal of Virology. 74: 4183-4191. PMID 10756031 DOI: 10.1128/Jvi.74.9.4183-4191.2000  0.51
2000 Hochleitner EO, Gorny MK, Zolla-Pazner S, Tomer KB. Mass spectrometric characterization of a discontinuous epitope of the HIV envelope protein HIV-gp120 recognized by the human monoclonal antibody 1331A Journal of Immunology. 164: 4156-4161. PMID 10754311 DOI: 10.4049/Jimmunol.164.8.4156  0.55
2000 Gorny MK, Vancott TC, Williams C, Revesz K, Zolla-Pazner S. Effects of oligomerization on the epitopes of the human immunodeficiency virus type 1 envelope glycoproteins Virology. 267: 220-228. PMID 10662617 DOI: 10.1006/Viro.1999.0095  0.497
1999 Lallos LB, Laal S, Hoxie JA, Zolla-Pazner S, Bandres JC. Exclusion of HIV coreceptors CXCR4, CCR5, and CCR3 from the HIV envelope Aids Research and Human Retroviruses. 15: 895-897. PMID 10408726 DOI: 10.1089/088922299310601  0.53
1999 Cecilia D, Kleeberger C, Muñoz A, Giorgi JV, Zolla-Pazner S. A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects Journal of Infectious Diseases. 179: 1365-1374. PMID 10228056 DOI: 10.1086/314773  0.468
1999 Hioe CE, Hildreth JEK, Zolla-Pazner S. Enhanced HIV type 1 neutralization by human anti-glycoprotein 120 monoclonal antibodies in the presence of monoclonal antibodies to lymphocyte function-associated molecule 1 Aids Research and Human Retroviruses. 15: 523-531. PMID 10221529 DOI: 10.1089/088922299311042  0.633
1999 Zolla-Pazner S, Gomy MK, Nyambi PN. The implications of antigenic diversity for vaccine development Immunology Letters. 66: 159-164. PMID 10203049 DOI: 10.1016/S0165-2478(98)00176-X  0.599
1999 Zolla-Pazner S, Gorny MK, Nyambi PN, VanCott TC, Nádas A. Immunotyping of human immunodeficiency virus type 1 (HIV): An approach to immunologic classification of HIV Journal of Virology. 73: 4042-4051. PMID 10196300 DOI: 10.1128/Jvi.73.5.4042-4051.1999  0.556
1999 Gigler A, Dorsch S, Hemauer A, Williams C, Kim S, Young NS, Zolla-Pazner S, Wolf H, Gorny MK, Modrow S. Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins Journal of Virology. 73: 1974-1979. PMID 9971777 DOI: 10.1128/Jvi.73.3.1974-1979.1999  0.511
1998 Lim HW, Pereira A, Sassa S, Kim M, Zolla-Pazner S. Early-stage HIV infection and hepatitis C virus infection are associated with elevated serum porphyrin levels Journal of the American Academy of Dermatology. 39: 956-959. PMID 9843008  0.349
1998 Hioe CE, Bastiani L, Hildreth JEK, Zolla-Pazner S. Role of cellular adhesion molecules in HIV type 1 infection and their impact on virus neutralization Aids Research and Human Retroviruses. 14. PMID 9814951  0.49
1998 Samanich KM, Belisle JT, Sonnenberg MG, Keen MA, Zolla-Pazner S, Laal S. Delineation of human antibody responses to culture filtrate antigens of Mycobacterium tuberculosis. The Journal of Infectious Diseases. 178: 1534-8. PMID 9780282 DOI: 10.1086/314438  0.355
1998 Zolla-Pazner S. Neutralization of syncytium-inducing primary isolates by sera from human immunodeficiency virus (HlV)-uninfected recipients of candidate HIV vaccines Journal of Infectious Diseases. 178: 1502-1506. PMID 9780275 DOI: 10.1086/314452  0.55
1998 Nyambi PN, Gorny MK, Bastiani L, Van Der Groen G, Williams C, Zolla-Pazner S. Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: A new strategy for studying the immunologic relatedness of HIV-1 Journal of Virology. 72: 9384-9391. PMID 9765494 DOI: 10.1128/Jvi.72.11.9384-9391.1998  0.631
1998 Cecilia D, Kewalramanl VN, O'Leary J, Volsky B, Nyambi P, Burda S, Xu S, Littman DR, Zolla-Pazner S. Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage Journal of Virology. 72: 6988-6996. PMID 9696790 DOI: 10.1128/Jvi.72.9.6988-6996.1998  0.578
1998 Inouye P, Cherry E, Hsu M, Zolla-Pazner S, Wainberg MA. Neutralizing antibodies directed against the V3 loop select for different escape variants in a virus with mutated reverse transcriptase (M184V) than in wild-type human immunodeficiency virus type 1 Aids Research and Human Retroviruses. 14: 735-740. PMID 9643373 DOI: 10.1089/Aid.1998.14.735  0.568
1998 Haigwood NL, Zolla-Pazner S. Humoral immunity to HIV, SIV, and SHIV Aids (London, England). 12. PMID 9632993  0.404
1998 Clements-Mann ML, Weinhold K, Matthews TJ, Graham BS, Gorse GJ, Keefer MC, McElrath MJ, Hsieh RH, Mestecky J, Zolla-Pazner S, Mascola J, Schwartz D, Siliciano R, Corey L, Wright PF, et al. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. The Journal of Infectious Diseases. 177: 1230-46. PMID 9593008 DOI: 10.1086/515288  0.59
1998 Andrus L, Prince AM, Bernal I, McCormack P, Lee DH, Gorny MK, Zolla-Pazner S. Passive immunization with a human immunodeficiency virus type 1-neutralizing monoclonal antibody in Hu-PBL-SCID mice: isolation of a neutralization escape variant. The Journal of Infectious Diseases. 177: 889-97. PMID 9534960 DOI: 10.1086/515251  0.531
1998 Li A, Katinger H, Posner MR, Cavacini L, Zolla-Pazner S, Gorny MK, Sodroski J, Chou TC, Baba TW, Ruprecht RM. Synergistic neutralization of simian-human immunodeficiency virus SHIV- vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins Journal of Virology. 72: 3235-3240. PMID 9525650 DOI: 10.1128/Jvi.72.4.3235-3240.1998  0.6
1998 LaCasse RA, Follis KE, Moudgil T, Trahey M, Binley JM, Planelles V, Zolla-Pazner S, Nunberg JH. Coreceptor utilization by human immunodeficiency virus type 1 is not a primary determinant of neutralization sensitivity Journal of Virology. 72: 2491-2495. PMID 9499111 DOI: 10.1128/Jvi.72.3.2491-2495.1998  0.441
1998 Gorny MK, Mascola JR, Israel ZR, VanCott TC, Williams C, Balfe P, Hioe C, Brodine S, Burda S, Zolla-Pazner S. A human monoclonal antibody specific for the V3 loop of HIV type 1 clade E cross-reacts with other HIV type 1 clades Aids Research and Human Retroviruses. 14: 213-221. PMID 9491911 DOI: 10.1089/Aid.1998.14.213  0.593
1998 Zolla-Pazner S, Lubeck M, Xu S, Burda S, Natuk RJ, Sinangil F, Steimer K, Gallo RC, Eichberg JW, Matthews T, Robert-Guroff M. Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees. Journal of Virology. 72: 1052-9. PMID 9444999 DOI: 10.1128/Jvi.72.2.1052-1059.1998  0.589
1997 Boots LJ, McKenna PM, Arnold BA, Keller PM, Gorny MK, Zolla-Pazner S, Robinson JE, Conley AJ. Anti-human immunodeficiency virus type 1 human monoclonal antibodies that bind discontinuous epitopes in the viral glycoproteins can identify mimotopes from recombinant phage peptide display libraries. Aids Research and Human Retroviruses. 13: 1549-59. PMID 9430247 DOI: 10.1089/Aid.1997.13.1549  0.558
1997 Gorny MK, VanCott TC, Hioe C, Israel ZR, Michael NL, Conley AJ, Williams C, Kessler JA, Chigurupati P, Burda S, Zolla-Pazner S. Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity. Journal of Immunology (Baltimore, Md. : 1950). 159: 5114-22. PMID 9366441  0.536
1997 Hioe CE, Xu S, Chigurupati P, Burda S, Williams C, Gorny MK, Zolla-Pazner S. Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies. International Immunology. 9: 1281-90. PMID 9310831 DOI: 10.1093/Intimm/9.9.1281  0.609
1997 Hill CM, Deng H, Unutmaz D, Kewalramani VN, Bastiani L, Gorny MK, Zolla-Pazner S, Littman DR. Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor Journal of Virology. 71: 6296-6304. PMID 9261346 DOI: 10.1128/Jvi.71.9.6296-6304.1997  0.537
1997 Hioe C, Burda S, Chigurupati P, Xu S, Zolla-Pazner S. Resting cell neutralization assay for HIV-1 primary isolates. Methods (San Diego, Calif.). 12: 300-5. PMID 9245610 DOI: 10.1006/Meth.1997.0483  0.564
1997 Laal S, Samanich KM, Sonnenberg MG, Belisle JT, O'Leary J, Simberkoff MS, Zolla-Pazner S. Surrogate marker of preclinical tuberculosis in human immunodeficiency virus infection: Antibodies to an 88-kDa secreted antigen of Mycobacterium tuberculosis Journal of Infectious Diseases. 176: 133-143. PMID 9207359 DOI: 10.1086/514015  0.523
1997 Lubeck MD, Natuk R, Myagkikh M, Kalyan N, Aldrich K, Sinangil F, Alipanah S, Murthy SC, Chanda PK, Nigida SM, Markham PD, Zolla-Pazner S, Steimer K, Wade M, Reitz MS, et al. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nature Medicine. 3: 651-8. PMID 9176492 DOI: 10.1038/Nm0697-651  0.524
1997 Li AN, Baba TW, Sodroski J, Zolla-Pazner S, Gorny MK, Robinson J, Posner MR, Katinger H, Barbas CF, Burton DR, Chou TC, Ruprecht RM. Synergistic neutralization of a chimetic SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins Aids Research and Human Retroviruses. 13: 647-656. PMID 9168233 DOI: 10.1089/Aid.1997.13.647  0.632
1997 Stamatatos L, Zolla-Pazner S, Gorny MK, Cheng-Mayer C. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: Effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells Virology. 229: 360-369. PMID 9126249 DOI: 10.1006/viro.1997.8443  0.568
1997 Israel ZR, Gorny MK, Palmer C, McKeating JA, Zolla-Pazner S. Prevalence of a V2 epitope in clade B primary isolates and its recognition by sera from HIV-1-infected individuals [4] Aids. 11: 128-130. PMID 9110092  0.45
1997 Bastiani L, Laal S, Kim M, Zolla-Pazner S. Host cell-dependent alterations in envelope components of human immunodeficiency virus type 1 virions Journal of Virology. 71: 3444-3450. PMID 9094615 DOI: 10.1128/Jvi.71.5.3444-3450.1997  0.399
1997 Zolla-Pazner S, Alving C, Belshe R, Berman P, Burda S, Chigurupati P, Clements ML, Duliege AM, Excler JL, Hioe C, Kahn J, McElrath MJ, Sharpe S, Sinangil F, Steimer K, et al. Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines. The Journal of Infectious Diseases. 175: 764-74. PMID 9086128 DOI: 10.1086/513969  0.557
1997 Heeney JL, Bruck C, Goudsmit J, Montagnier L, Schultz A, Tyrrell D, Zolla-Pazner S. Immune correlates of protection from HIV infection and AIDS. Immunology Today. 18: 4-8. PMID 9018965 DOI: 10.1016/S0167-5699(97)80005-9  0.478
1997 Bandres JC, Wang QF, O'Leary J, Hoxie JA, Zolla-Pazner S, Gorny M. HIV envelope deglycosylation increases binding of this molecule to CXCR4 Clinical Infectious Diseases. 25: 392.  0.419
1996 Zolla-Pazner S. Mechanisms contributing to the neutralization of HIV-1 Immunology Letters. 51: 89-93. PMID 8811350 DOI: 10.1016/0165-2478(96)02560-6  0.555
1996 Seligman SJ, Binley JM, Gorny MK, Burton DR, Zolla-Pazner S, Sokolowski KA. Characterization by serial deletion competition ELISAs of HIV-1 V3 loop epitopes recognized by monoclonal antibodies. Molecular Immunology. 33: 737-45. PMID 8811069 DOI: 10.1016/0161-5890(96)00044-2  0.541
1996 Gorny MK, Keler T, Burda S, Williams C, Gabriel JL, Mitchell WM, Deo YM, Zolla-Pazner S. Functional studies of bispecific antibodies directed against HIV-1 and the Fc gamma I receptor type I. Antibiotics and Chemotherapy. 48: 173-83. PMID 8726522 DOI: 10.1159/000425174  0.528
1996 Nomura N, Zolla-Pazner S, Simberkoff M, Kim M, Sassa S, Lim HW. Abnormal serum porphyrin levels in patients with the acquired immunodeficiency syndrome with or without hepatitis C virus infection Archives of Dermatology. 132: 906-910. PMID 8712840 DOI: 10.1001/Archderm.132.8.906  0.46
1995 Zolla-Pazner S, Sharpe S. A resting cell assay for improved detection of antibody-mediated neutralization of HIV type 1 primary isolates. Aids Research and Human Retroviruses. 11: 1449-1458. PMID 8679288 DOI: 10.1089/Aid.1995.11.1449  0.56
1995 Rovinski B, Rodrigues L, Cao SX, Yao FL, McGuinness U, Sia C, Cates G, Zolla-Pazner S, Karwowska S, Matthews TJ. Induction of HIV type 1 neutralizing and env-CD4 blocking antibodies by immunization with genetically engineered HIV type 1-like particles containing unprocessed gp160 glycoproteins. Aids Research and Human Retroviruses. 11: 1187-95. PMID 8573374 DOI: 10.1089/Aid.1995.11.1187  0.552
1995 Forthal DN, Landucci G, Gorny MK, Zolla-Pazner S, Robinson WE. Functional activities of 20 human immunodeficiency virus type 1 (HIV-1)-specific human monoclonal antibodies. Aids Research and Human Retroviruses. 11: 1095-1099. PMID 8554906 DOI: 10.1089/Aid.1995.11.1095  0.59
1995 Fontenot JD, VanCott TC, Parekh BS, Pau CP, George JR, Birx DL, Zolla-Pazner S, Gorny MK, Gatewood JM. Presentation of HIV V3 loop epitopes for enhanced antigenicity, immunogenicity and diagnostic potential. Aids (London, England). 9: 1121-9. PMID 8519447 DOI: 10.1097/00002030-199510000-00002  0.588
1995 Sattentau QJ, Zolla-Pazner S, Poignard P. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology. 206: 713-717. PMID 7530400 DOI: 10.1016/S0042-6822(95)80094-8  0.56
1995 Nomura N, Fotiades J, Zolla-Pazner S, Simberkoff M, Kim M, Sassa S, Lim HW. 046 Serum porphyrin study in patients with HIV infection Journal of Dermatological Science. 10: 70. DOI: 10.1016/0923-1811(95)93758-S  0.48
1994 Conley AJ, Gorny MK, Kessler JA, Boots LJ, Ossorio-Castro M, Koenig S, Lineberger DW, Emini EA, Williams C, Zolla-Pazner S. Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. Journal of Virology. 68: 6994-7000. PMID 7933081 DOI: 10.1128/Jvi.68.11.6994-7000.1994  0.6
1994 Zolla-Pazner S, Laal S, Burda S, Buchbinder A. Human Monoclonal Antibodies to HIV-1 Define Synergistic Activities Leading to Enhanced Neutralization1 Antibiotics and Chemotherapy. 46: 38-47. PMID 7826038 DOI: 10.1159/000423632  0.581
1994 Gorny MK, Moore JP, Conley AJ, Karwowska S, Sodroski J, Williams C, Burda S, Boots LJ, Zolla-Pazner S. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1 Journal of Virology. 68: 8312-8320. PMID 7525987 DOI: 10.1128/Jvi.68.12.8312-8320.1994  0.585
1993 Arakelov S, Gorny MK, Williams C, Riggin CH, Brady F, Collett MS, Zolla-Pazner S. Generation of neutralizing anti-B19 parvovirus human monoclonal antibodies from patients infected with human immunodeficiency virus. The Journal of Infectious Diseases. 168: 580-5. PMID 8354899 DOI: 10.1093/Infdis/168.3.580  0.544
1993 Laal S, Burda S, Sharpe S, Zolla-Pazner S. A rapid, automated microtiter assay for measuring neutralization of HIV-1. Aids Research and Human Retroviruses. 9: 781-785. PMID 8217345 DOI: 10.1089/Aid.1993.9.781  0.549
1993 Manca F, Seravalli E, Valle MT, Fenoglio D, Kunkl A, Pira GL, Zolla-Pazner S, Celada F. Non-covalent complexes of HIV gp120 with CD4 and/or mAbs enhance activation of gp120-specific T clones and provide intermolecular help for anti-CD4 antibody production. International Immunology. 5: 1109-1117. PMID 7902128 DOI: 10.1093/Intimm/5.9.1109  0.425
1993 Keller PM, Arnold BA, Shaw AR, Tolman RL, Van Middlesworth F, Bondy S, Rusiecki VK, Koenig S, Zolla-Pazner S, Conard P, Emini EA, Conley AJ. Identification of HIV vaccine candidate peptides by screening random phage epitope libraries Virology. 193: 709-716. PMID 7681612 DOI: 10.1006/Viro.1993.1179  0.602
1993 Eddleston M, de La Torre JC, Xu JY, Dorfman N, Notkins A, Zolla-Pazner S, Oldstone MB. Molecular mimicry accompanying HIV-1 infection: human monoclonal antibodies that bind to gp41 and to astrocytes. Aids Research and Human Retroviruses. 9: 939-44. PMID 7506553 DOI: 10.1089/Aid.1993.9.939  0.611
1993 Laal S, Zolla-Pazner S. Epitopes of HIV-1 Glycoproteins Recognized by the Human Immune System Chemical Immunology. 56: 91-111. DOI: 10.1159/000319158  0.54
1992 Stickler MC, Sharpe S, Zolla-Pazner S. p24 antibody production in p24 antibody-negative HIV-infected subjects. Viral Immunology. 5: 123-132. PMID 1616583 DOI: 10.1089/Vim.1992.5.123  0.463
1992 Rovinski B, Haynes JR, Cao SX, James O, Sia C, Zolla-Pazner S, Matthews TJ, Klein MH. Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS vaccine. Journal of Virology. 66: 4003-12. PMID 1602531 DOI: 10.1128/Jvi.66.7.4003-4012.1992  0.59
1992 Buchbinder A, Karwowska S, Gorny MK, Burda ST, Zolla-Pazner S. Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strains. Aids Research and Human Retroviruses. 8: 425-427. PMID 1599752 DOI: 10.1089/Aid.1992.8.425  0.544
1992 Zolla-Pazner S, Gorny MK. Passive immunization for the prevention and treatment of HIV infection. Aids. 6: 1235-1247. PMID 1472330 DOI: 10.1097/00002030-199211000-00001  0.478
1992 McKeating JA, Thali M, Furman C, Karwowska S, Gorny MK, Cordell J, Zolla-Pazner S, Sodroski J, Weiss RA. Amino acid residues of the human immunodeficiency virus type I gp120 critical for the binding of rat and human neutralizing antibodies that block the gp120-sCD4 interaction. Virology. 190: 134-42. PMID 1382339 DOI: 10.1016/0042-6822(92)91199-5  0.495
1992 Karwowska S, Gorny MK, Buchbinder A, Gianakakos V, Williams C, Fuerst T, Zolla-Pazner S. Production of human monoclonal antibodies specific for conformational and linear non-V3 epitopes of gp120. Aids Research and Human Retroviruses. 8: 1099-1106. PMID 1380257 DOI: 10.1089/Aid.1992.8.1099  0.561
1992 Wang H, Müller S, Köhler H, Zolla-Pazner S. Human monoclonal and polyclonal anti-human immunodeficiency virus-1 antibodies share a common clonotypic specificity. European Journal of Immunology. 22: 1749-1755. PMID 1378015 DOI: 10.1002/Eji.1830220713  0.58
1991 Robinson WE, Gorny MK, Xu J, Mitchell WM, Zolla-Pazner S. Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro. Journal of Virology. 65: 4169-4176. PMID 2072448 DOI: 10.1128/Jvi.65.8.4169-4176.1991  0.599
1991 Gorny MK, Xu J, Gianakakos V, Karwowska S, Williams C, Sheppard HW, Hanson CV, Zolla-Pazner S. Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein. Proceedings of the National Academy of Sciences of the United States of America. 88: 3238-3242. PMID 2014246 DOI: 10.1073/Pnas.88.8.3238  0.544
1991 Edelman AS, Zolla-Pazner S. Proliferative response of mononuclear cells from HIV-infected patients to B-cell mitogens: effects of lymphocyte subset frequency, T-cell defects and prostaglandins. Aids Research and Human Retroviruses. 7: 953-961. PMID 1760232 DOI: 10.1089/Aid.1991.7.953  0.343
1990 Edelman AS, Zolla-Pazner S. Response of mononuclear cells from HIV-infected patients to B-cell mitogens: correlation with immunological and clinical features of disease progression. Aids. 4: 859-864. PMID 2147550 DOI: 10.1097/00002030-199009000-00004  0.42
1989 Gorny MK, Gianakakos V, Sharpe S, Zolla-Pazner S. Generation of human monoclonal antibodies to human immunodeficiency virus Proceedings of the National Academy of Sciences of the United States of America. 86: 1624-1628. PMID 2922401 DOI: 10.1073/Pnas.86.5.1624  0.616
1989 Pinter A, Honnen WJ, Tilley SA, Bona C, Zaghouani H, Gorny MK, Zolla-Pazner S. Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1. Journal of Virology. 63: 2674-2679. DOI: 10.1128/Jvi.63.6.2674-2679.1989  0.485
1988 Kopelman RG, Zolla-Pazner S. Association of human immunodeficiency virus infection and autoimmune phenomena The American Journal of Medicine. 84: 82-88. PMID 3257353 DOI: 10.1016/0002-9343(88)90012-5  0.429
1988 Kopelman RG, Zolla-Pazner S. Autoimmune phenomena in human immunodeficiency virus infection The American Journal of Medicine. 85: 284. DOI: 10.1016/S0002-9343(88)80376-0  0.385
1987 El-Sadr W, Marmor M, Zolla-Pazner S, Stahl RE, Lyden M, William D, D'Onofrio S, Weiss SH, Saxinger WC. Four-Year Prospective Study of Homosexual Men: Correlation of Immunologic Abnormalities, Clinical Status, and Serology to Human Immunodeficiency Virus The Journal of Infectious Diseases. 155: 789-793. PMID 3546522 DOI: 10.1093/Infdis/155.4.789  0.459
1987 Zolla-Pazner S, Pinter A, Mizuma H. Potential use of serotherapy in the prevention and treatment of infection with the human immunodeficiency virus. Journal of Virological Methods. 17: 45-53. PMID 3312267 DOI: 10.1016/0166-0934(87)90067-X  0.596
1986 Zolla-Pazner S. Immunologic Abnormalities in Infections With the Human Immunodeficiency Virus Labmedicine. 17: 685-689. DOI: 10.1093/Labmed/17.11.685  0.382
1984 Marmor M, Friedman-Kien AE, Zolla-Pazner S, Stahl RE, Rubinstein P, Laubenstein L, William DC, Klein RJ, Spigland I. Kaposi's Sarcoma in Homosexual Men: A Seroepidemiologic Case-Control Study Annals of Internal Medicine. 100: 809-815. PMID 6326631 DOI: 10.7326/0003-4819-100-6-809  0.35
1984 Zolla-Pazner S, William D, El-Sadr W, Marmor M, Stahl R. Quantitation of β2-Microglobulin and Other Immune Characteristics in a Prospective Study of Men at Risk for Acquired Immune Deficiency Syndrome Jama. 251: 2951-2955. DOI: 10.1001/Jama.1984.03340460029020  0.303
1983 Gallo RC, Sarin PS, Gelmann EP, Robert-Guroff M, Richardson E, Kalyanaraman VS, Mann D, Sidhu GD, Stahl RE, Zolla-Pazner S, Leibowitch J, Popovic M. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science (New York, N.Y.). 220: 865-7. PMID 6601823 DOI: 10.1126/Science.6601823  0.333
1983 Basch RS, Buxbaum JN, Zolla-pazner S. Identification of a new marker (Ly RL♂o1) for cells of the T lineage by an auto-antithymocyte serum Cellular Immunology. 81: 144-156. PMID 6225523 DOI: 10.1016/0008-8749(83)90220-4  0.38
1981 Zolla-Pazner S, Gilbert M, Fleit SA. Studies of antibody affinity in plasmacytoma-bearing mice: Evidence for a maturational defect of B lymphocytes Cellular Immunology. 62: 149-155. PMID 6973406 DOI: 10.1016/0008-8749(81)90308-7  0.356
Show low-probability matches.